Wall Street is positive on Sorrento Therapeutics Inc (SRNE). On average, analysts give SRNE a Strong Buy rating. The average price target is $26.666, which means analysts expect the stock to gain by 514.42% over the next twelve months. That average ranking earns SRNE an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating SRNE a Strong Buy today. Find out what this means to you and get the rest of the rankings on SRNE!